Molecular changes in mesothelioma with an impact on prognosis and treatment

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 3, 2012, Pages 277-293

  Jean, Didier ^a   Daubriac, Julien ^b   Le Pimpec Barthes, Françoise ^a,c   Galateau Salle, Françoise ^a   Jaurand, Marie Claude ^a  

^a INSERM   (France)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ARTICLE; CHROMOSOME ABERRATION; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MESOTHELIOMA; MULTIMODALITY CANCER THERAPY; PLEURA TUMOR; PROGNOSIS; SIGNAL TRANSDUCTION;

CHROMOSOME ABERRATIONS; COMBINED MODALITY THERAPY; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESOTHELIOMA; MICRORNAS; PLEURAL NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84858017101     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0215-RA     Document Type: Article

References (192)

1. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: mesothelioma. Cancer Genet Cytogenet. 2001;127(2):93-110. (Pubitemid 32586066)
2. Musti M, Kettunen E, Dragonieri S, et al. Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet. 2006;170(1):9-15. (Pubitemid 44349011)
3. Sekido Y. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci. 2010;101(1):1-6.
4. Gibas Z, Li FP, Antman KH, Bernal S, Stahel R, Sandberg AA. Chromosome changes in malignant mesothelioma. Cancer Genet Cytogenet. 1986;20(3-4):191-201. (Pubitemid 16153273)
5. Hagemeijer A, Versnel MA, Van Drunen E, et al. Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet. 1990;47(1):1-28. (Pubitemid 20223634)
6. Krismann M, Muller KM, Jaworska M, Johnen G. Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases. J Pathol. 2002; 197(3):363-371. (Pubitemid 34778307)
7. Lindholm PM, Salmenkivi K, Vauhkonen H, et al. Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH. Cytogenet Genome Res. 2007;119(1-2):46-52.
8. Taniguchi T, Karnan S, Fukui T, et al. Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci. 2007;98(3):438-446. (Pubitemid 46195618)
9. Ivanov SV, Miller J, Lucito R, et al. Genomic events associated with progression of pleural malignant mesothelioma. Int J Cancer. 2009;124(3):589-599.
10. Cheung M, Pei J, Pei Y, Jhanwar SC, Pass HI, Testa JR. The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival. Oncogene. 2010;29(11): 1633-1640.
11. Christensen BC, Houseman EA, Poage GM, et al. Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma. Cancer Res. 2010;70(14):5686-5694.
12. Jean D, Thomas E, Manie E, et al. Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma. Am J Pathol. 2011;178(2):881-894.
13. Bueno R, De Rienzo A, Dong L, et al. Second generation sequencing of the mesothelioma tumor genome. PLoS One. 2010;5(5):e10612. doi:10.1371/ journal.pone.0010612.
14. Lechner JF, Tokiwa T, LaVeck M, et al. Asbestos-associated chromosomal changes in human mesothelial cells. Proc Natl Acad Sci U S A. 1985;82(11): 3884-3888. (Pubitemid 15246457)
15. Jaurand MC, Renier A, Daubriac J. Mesothelioma: do asbestos and carbon nanotubes pose the same health risk? Part Fibre Toxicol. 2009;6:16.
16. Tiainen M, Tammilehto L, Rautonen J, Tuomi T, Mattson K, Knuutila S. Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma. Br J Cancer. 1989;60(4):618-626. (Pubitemid 19251463)
17. Tammilehto L, Tuomi T, Tiainen M, et al. Malignant mesothelioma: clinical characteristics, asbestos mineralogy and chromosomal abnormalities of 41 patients. Eur J Cancer. 1992;28A(8-9):1373-1379.
18. Illei PB, Ladanyi M, Rusch VW, Zakowski MF. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer. 2003;99(1):51-56. (Pubitemid 36267967)
19. Savic S, Franco N, Grilli B, et al. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest. 2010; 138(1):137-144.
20. Chung CT, Santos Gda C, Hwang DM, et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol. 2010;63(7):630-634.
21. Bjorkqvist AM, Tammilehto L, Nordling S, et al. Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. Br J Cancer. 1998;77(2):260-269. (Pubitemid 28029543)
22. Knuuttila A, Jee KJ, Taskinen E, Wolff H, Knuutila S, Anttila S. Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases. Virchows Arch. 2006;448(2):135-141. (Pubitemid 43237878)
23. Tiainen M, Rautonen J, Pyrhonen S, Tammilehto L, Mattson K, Knuutila S. Chromosome number correlates with survival in patients with malignant pleural mesothelioma. Cancer Genet Cytogenet. 1992;62(1):21-24.
24. Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res. 2003;9(6):2108-2113. (Pubitemid 36687632)
25. Lopez-Rios F, Chuai S, Flores R, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006;66(6):2970-2979.
26. Scattone A, Pennella A, Gentile M, et al. Comparative genomic hybridisation in malignant deciduoid mesothelioma. J Clin Pathol. 2006;59(7): 764-769. (Pubitemid 44048790)
27. Kamatani N, Nelson-Rees WA, Carson DA. Selective killing of human malignant cell lines deficient in methylthioadenosine phosphorylase, a purine metabolic enzyme. Proc Natl Acad Sci U S A. 1981;78(2):1219-1223. (Pubitemid 11102192)
28. Kindler HL, Burris HA III, Sandler AB, Oliff IA. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Invest New Drugs. 2009;27(1):75-81.
29. Lee AY, He B, You L, et al. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene. 2004; 23(39):6672-6676. (Pubitemid 39265531)
30. He B, Lee AY, Dadfarmay S, et al. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res. 2005;65(3):743-748. (Pubitemid 40216431)
31. Batra S, Shi Y, Kuchenbecker KM, et al. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun. 2006;342(4):1228-1232.
32. Kohno H, Amatya VJ, Takeshima Y, et al. Aberrant promoter methylation of WIF-1 and SFRP1, 2, 4 genes in mesothelioma. Oncol Rep. 2010;24(2):423-431.
33. Christensen BC, Houseman EA, Godleski JJ, et al. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res. 2009;69(1):227-234.
34. Goto Y, Shinjo K, Kondo Y, et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res. 2009;69(23): 9073-9082.
35. Toyooka S, Pass HI, Shivapurkar N, et al. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res. 2001;61(15): 5727-5730. (Pubitemid 32769086)
36. Tsou JA, Shen LY, Siegmund KD, et al. Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. Lung Cancer. 2005;47(2):193-204. (Pubitemid 40082162)
37. Marsit CJ, Houseman EA, Christensen BC, et al. Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res. 2006;66(21):10621-10629. (Pubitemid 44799786)
38. Richardson B. Impact of aging on DNA methylation. Ageing Res Rev. 2003;2(3):245-261. (Pubitemid 38340315)
39. Christensen BC, Godleski JJ, Marsit CJ, et al. Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis. 2008;29(8):1555-1559.
40. Tomii K, Tsukuda K, Toyooka S, et al. Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer. 2007;120(3):566-573. (Pubitemid 44969028)
41. Kimura K, Toyooka S, Tsukuda K, et al. The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas. Oncol Rep. 2008; 20(5):1265-1268.
42. Shivapurkar N, Toyooka S, Toyooka KO, et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer. 2004; 109(5):786-792. (Pubitemid 38405630)
43. Tsou JA, Galler JS, Wali A, et al. DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer. 2007;58(2):220-230. (Pubitemid 47513257)
44. Christensen BC, Marsit CJ, Houseman EA, et al. Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles. Cancer Res. 2009;69(15):6315-6321.
45. Suzuki M, Toyooka S, Shivapurkar N, et al. Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection. Oncogene. 2005;24(7):1302-1308. (Pubitemid 40313933)
46. Paik PK, Krug LM. Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol. 2010;5(2): 275-279.
47. Guled M, Lahti L, Lindholm PM, et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma: a miRNA microarray analysis. Genes Chromosomes Cancer. 2009;48(7):615-623.
48. Busacca S, Germano S, De Cecco L, et al. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol. 2010;42(3):312-319.
49. Gee GV, Koestler DC, Christensen BC, et al. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer. 2010;127(12):2859-2869.
50. Ivanov SV, Goparaju CM, Lopez P, et al. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem. 2010;285(30):22809-22817.
51. Pass HI, Goparaju C, Ivanov S, et al. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res. 2010;70(5):1916-1924.
52. Benjamin H, Lebanony D, Rosenwald S, et al. A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn. 2010;12(6):771-779.
53. Zekri AR, Bahnassy AA, Mohamed WS, et al. Evaluation of simian virus-40 as a biological prognostic factor in Egyptian patients with malignant pleural mesothelioma. Pathol Int. 2007;57(8):493-501. (Pubitemid 47030133)
54. Jaurand MC, Fleury-Feith J. Pathogenesis of malignant pleural mesothe-lioma. Respirology. 2005;10(1):2-8.
55. Gee GV, Stanifer ML, Christensen BC, et al. SV40 associated miRNAs are not detectable in mesotheliomas. Br J Cancer. 2010;103(6):885-888.
56. Bianchi AB, Mitsunaga S, Cheng J, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesothelioma. Proc Natl Acad Sci U S A. 1995;92(24):10854-10858.
57. Sekido Y, Pass HI, Bader S, Mew DJ, Christmas MF, Gazdar AF. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995;55(6):1227-1231.
58. Tiainen M, Tammilehto L, Mattson K, Knuutila S. Nonrandom chromosomal abnormalities in malignant pleural mesothelioma. Cancer Genet Cyto-genet. 1988;33(2):251-274.
59. Flejter WL, Li FP, Antman KH, Testa JR. Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possibles sites of tumor suppressor genes. Genes Chromosomes Cancer. 1989;1(2):148-154. (Pubitemid 20094559)
60. Lecomte C, Andujar P, Renier A, et al. Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma. Cell Cycle. 2005;4(12):1862-1869. (Pubitemid 41827334)
61. INK4A inactivation mechanisms in non small-cell lung cancer patients occupationally exposed to asbestos. Lung Cancer. 2010;67(1):23-30.
62. Xiao S, Li DZ, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene. 1995;11(3):511-515.
63. Takeda M, Kasai T, Enomoto Y, et al. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int. 2010;60(5):395-399.
64. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994;54(21): 5547-5551.
65. Kratzke RA, Otterson G, Lincoln CE, et al. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst. 1995;87(24):1870-1875. (Pubitemid 3012655)
66. Ladanyi M. Implications of P16/CDKN2A deletion in pleural mesotheli-omas. Lung Cancer. 2005;49(suppl 1):S95-S98. (Pubitemid 40798856)
67. Dacic S, Kothmaier H, Land S, et al. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch. 2008;453(6):627-635.
68. Shigemitsu K, Sekido Y, Usami N, et al. Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene. 2001;20(31): 4249-4257. (Pubitemid 32762199)
69. Uematsu K, Kanazawa S, You L, et al. Wnt pathway activation in mesothelioma: evidence of dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res. 2003;63(15):4547-4551. (Pubitemid 36951028)
70. Gray SG, Fennell DA, Mutti L, O'Byrne KJ. In arrayed ranks: array technology in the study of mesothelioma. J Thorac Oncol. 2009;4(3):411-425.
71. Kettunen E, Nissen AM, Ollikainen T, et al. Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. Int J Cancer. 2001;91(4): 492-496. (Pubitemid 32115103)
72. Mohr S, Keith G, Galateau-Salle F, Icard P, Rihn BH. Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray. Biochim Biophys Acta. 2004;1688(1):43-60. (Pubitemid 38366304)
73. Mohr S, Bottin MC, Lannes B, et al. Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells. Biochimie. 2004;86(1):13-19. (Pubitemid 38264274)
74. Kettunen E, Nicholson AG, Nagy B, et al. L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray. Carcinogenesis. 2005;26(1):17-25. (Pubitemid 40207695)
75. Gordon GJ, Rockwell GN, Jensen RV, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol. 2005;166(6):1827-1840. (Pubitemid 40734405)
76. Singhal S, Wiewrodt R, Malden LD, et al. Gene expression profiling of malignant mesothelioma. Clin Cancer Res. 2003;9(8):3080-3097. (Pubitemid 36993271)
77. Crispi S, Calogero RA, Santini M, et al. Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS One. 2009;4(9):e7016. doi:10.1371/ journal.pone.0007016.
78. Romagnoli S, Fasoli E, Vaira V, et al. Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis. Am J Pathol. 2009;174(3):762-770.
79. Ivanova AV, Ivanov SV, Prudkin L, et al. Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer. 2009;8:91.
80. Hoang CD, D'Cunha J, Kratzke MG, et al. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest. 2004; 125(5):1843-1852. (Pubitemid 38648420)
81. Gordon GJ, Jensen RV, Hsiao LL, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst. 2003; 95(8):598-605. (Pubitemid 36553506)
82. Gordon GJ, Rockwell GN, Godfrey PA, et al. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res. 2005;11(12):4406-4414. (Pubitemid 40825631)
83. Gordon GJ, Dong L, Yeap BY, et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst. 2009;101(9):678-686.
84. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005;115(6):1503-1521. (Pubitemid 40814659)
85. Crispi S, Fagliarone C, Biroccio A, et al. Antiproliferative effect of Aurora kinase targeting in mesothelioma. Lung Cancer. 2010;70(3):271-279.
86. Ivanova AV, Goparaju CM, Ivanov SV, et al. Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma. Clin Cancer Res. 2009;15(8):2602-2611.
87. Yang X, Sun X. Meta-analysis of several gene lists for distinct types of cancer: a simple way to reveal common prognostic markers. BMC Bioinfor-matics. 2007;8(1):118.
88. Roe OD, Anderssen E, Sandeck H, Christensen T, Larsson E, Lundgren S. Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer. 2010;67(1):57-68.
89. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117-1134.
90. Edwards JG, Swinson DE, Jones JL, Waller DA, O'Byrne KJ. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer. 2006;54(3):399-407. (Pubitemid 44634142)
91. Kothmaier H, Quehenberger F, Halbwedl I, et al. EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors. Thorax. 2008;63(4):345-351. (Pubitemid 351497948)
92. Destro A, Ceresoli GL, Falleni M, et al. EGFR overexpression in malignant pleural mesothelioma: an immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer. 2006;51(2):207-215. (Pubitemid 43144364)
93. Agarwal V, Lind MJ, Cawkwell L. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand? [published online ahead of print December 21, 2010]. Cancer Treat Rev. doi:10.1016/j.ctrv.2010. 11.004.
94. Govindan R, Kratzke RA, Herndon JE II, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005;11(6):2300-2304. (Pubitemid 40490190)
95. Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008; 113(4):808-814.
96. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol. 2007;25(17):2406-2413. (Pubitemid 46999211)
97. Butnor KJ, Burchette JL, Sporn TA, Hammar SP, Roggli VL. The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature. Arch Pathol Lab Med. 2004;128(5):538-543. (Pubitemid 38579591)
98. Horvai AE, Li L, Xu Z, Kramer MJ, Jablons DM, Treseler PA. c-Kit is not expressed in malignant mesothelioma. Mod Pathol. 2003;16(8):818-822. (Pubitemid 37011078)
99. Lee AY, Raz DJ, He B, Jablons DM. Update on the molecular biology of malignant mesothelioma. Cancer. 2007;109(8):1454-1461. (Pubitemid 46595678)
100. Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol. 1999;189(1):72-78. (Pubitemid 29406822)
101. Aoe K, Hiraki A, Tanaka T, et al. Expression of vascular endothelial growth factor in malignant mesothelioma. Anticancer Res. 2006;26(6C):4833-4836. (Pubitemid 46032120)
102. Demirag F, Unsal E, Yilmaz A, Caglar A. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest. 2005;128(5):3382-3387. (Pubitemid 41698667)
103. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer. 1999;81(1):54-61. (Pubitemid 29415491)
104. Konig J, Tolnay E, Wiethege T, Muller K. Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesotheli-oma. Respiration. 2000;67(1):36-40. (Pubitemid 30114163)
105. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001; 193(4):468-475. (Pubitemid 32266815)
106. Filho AL, Baltazar F, Bedrossian C, Michael C, Schmitt FC. Immunohis-tochemical expression and distribution of VEGFR-3 in malignant mesothelioma. Diagn Cytopathol. 2007;35(12):786-791. (Pubitemid 350250764)
107. Masood R, Kundra A, Zhu S, et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer. 2003;104(5):603-610. (Pubitemid 36337260)
108. Romano M, Catalano A, Nutini M, et al. 5-Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. FASEB J. 2001;15(13):2326-2336. (Pubitemid 33063161)
109. Pasello G, Favaretto A. Molecular targets in malignant pleural mesothelioma treatment. Curr Drug Targets. 2009;10(12):1235-1244.
110. Gerwin BI, Lechner JF, Reddel RR, et al. Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res. 1987;47(23): 6180-6184. (Pubitemid 18011059)
111. Versnel MA, Claesson-Welsh L, Hammacher A, et al. Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene. 1991;6(11):2005-2011. (Pubitemid 21924040)
112. Ramael M, Buysse C, van den Bossche J, Segers K, van Marck E. Immunoreactivity for the beta chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium. J Pathol. 1992; 167(1):1-4.
113. Zhong J, Gencay MM, Bubendorf L, et al. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells. J Cell Physiol. 2006; 207(2):540-552.
114. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 2004;15(4):197-204. (Pubitemid 38781045)
115. Heldin P, Asplund T, Ytterberg D, Thelin S, Laurent TC. Characterization of the molecular mechanism involved in the activation of hyaluronan synthetase by platelet-derived growth factor in human mesothelial cells. Biochem J. 1992; 283(pt 1):165-170.
116. Jacobson A, Brinck J, Briskin MJ, Spicer AP, Heldin P. Expression of human hyaluronan synthases in response to external stimuli. Biochem J. 2000; 348(pt 1):29-35. (Pubitemid 30312127)
117. Van der Meeren A, Seddon MB, Betsholtz CA, Lechner JF, Gerwin BI. Tumorigenic conversion of human mesothelial cells as a consequence of platelet-derived growth factor-A chain overexpression. Am J Respir Cell Mol Biol. 1993; 8(2):214-221.
118. Metheny-Barlow LJ, Flynn B, van Gijssel HE, Marrogi A, Gerwin BI. Paradoxical effects of platelet-derived growth factor-A overexpression in malignant mesothelioma: antiproliferative effects in vitro and tumorigenic stimulation in vivo. Am J Respir Cell Mol Biol. 2001;24(6):694-702. (Pubitemid 32550591)
119. Mathy A, Baas P, Dalesio O, van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer. 2005;50(1):83-86. (Pubitemid 41297473)
120. Porta C, Mutti L, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2007;59(1):149-150. (Pubitemid 44796113)
121. Whitson BA, Kratzke RA. Molecular pathways in malignant pleural mesothelioma. Cancer Lett. 2006;239(2):183-189. (Pubitemid 43996826)
122. Jaurand MC, Fleury-Feith J. Mesothelial cells. In: Light RW, Lee YCG, eds. Textbook of Pleural Diseases. 2nd ed. London, United Kingdom: Hodder Arnold; 2008:27-37.
123. Hoang CD, Zhang X, Scott PD, et al. Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. Cancer Res. 2004;64(20):7479-7485. (Pubitemid 39372091)
124. Lee TC, Zhang Y, Aston C, et al. Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. Cancer Res. 1993;53(12):2858-2864. (Pubitemid 23180528)
125. Liu Z, Klominek J. Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors. Thorax. 2003;58(3):198-203. (Pubitemid 36307996)
126. Kawaguchi K, Murakami H, Taniguchi T, et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis. 2009;30(7):1097-1105.
127. Jagadeeswaran R, Ma PC, Seiwert TY, et al. Functional analysis of c-Met/ hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006;66(1):352-361. (Pubitemid 43166042)
128. Tolnay E, Kuhnen C, Wiethege T, Konig JE, Voss B, Muller KM. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol. 1998;124(6):291-296. (Pubitemid 28332909)
129. Thirkettle I, Harvey P, Hasleton PS, Ball RY, Warn RM. Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas. Histopathology. 2000;36(6):522-528. (Pubitemid 30348777)
130. Harvey P, Warn A, Dobbin S, et al. Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology. Br J Cancer. 1998;77(7):1052-1059. (Pubitemid 28116274)
131. Mukohara T, Civiello G, Davis IJ, et al. Inhibition of the met receptor in mesothelioma. Clin Cancer Res. 2005;11(22):8122-8130. (Pubitemid 41698757)
132. de Melo M, Gerbase MW, Curran J, Pache JC. Phosphorylated extracellular signal-regulated kinases are significantly increased in malignant mesothelioma. J Histochem Cytochem. 2006;54(8):855-861. (Pubitemid 44106863)
133. Vintman L, Nielsen S, Berner A, Reich R, Davidson B. Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells. Cancer. 2005;103(11):2427-2433. (Pubitemid 40686590)
134. Eguchi R, Fujimori Y, Takeda H, et al. Arsenic trioxide induces apoptosis through JNK and ERK in human mesothelioma cells. J Cell Physiol. 2011;226(3): 762-768.
135. Ou WB, Hubert C, Corson JM, et al. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Neoplasia. 2011;13(1):12-22.
136. Roth M, Zhong J, Tamm M, Szilard J. Mesothelioma cells escape heat stress by upregulating Hsp40/Hsp70 expression via mitogen-activated protein kinases. J Biomed Biotechnol. 2009;2009:451084.
137. Besson A, Robbins SM, Yong VW. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur J Biochem. 1999;263(3):605-611. (Pubitemid 29361932)
138. Daubriac J, Fleury-Feith J, Kheuang L, et al. Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates. Cell Death Differ. 2009;16(8):1146-1155.
139. Altomare DA, You H, Xiao GH, et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene. 2005;24(40):6080-6089. (Pubitemid 43080058)
140. Suzuki Y, Murakami H, Kawaguchi K, et al. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Report. 2009;2(2):181-188.
141. Opitz I, Soltermann A, Abaecherli M, et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg. 2008; 33(3):502-506.
142. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127(3):469-480.
143. Lee AY, He B, You L, et al. Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma. Biochem Biophys Res Commun. 2004;323(4):1246-1250. (Pubitemid 39296559)
144. Mazieres J, You L, He B, et al. Wnt2 as a new therapeutic target in malignant pleural mesothelioma. Int J Cancer. 2005;117(2):326-332. (Pubitemid 41377454)
145. Kashiwakura Y, Ochiai K, Watanabe M, et al. Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis. Cancer Res. 2008; 68(20):8333-8341.
146. Yokoyama T, Osada H, Murakami H, et al. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis. 2008;29(11):2139-2146.
147. Murakami H, Mizuno T, Taniguchi T, et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 2011;71(3):873-883.
148. Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer. 2009;64(2):140-147.
149. Xiao GH, Gallagher R, Shetler J, et al. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol. 2005;25(6):2384-2394. (Pubitemid 40354632)
150. Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, Testa JR. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesotheli-oma cells and negatively regulates FAK. Oncogene. 2006;25(44):5960- 5968. (Pubitemid 44477290)
151. Lopez-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG. Loss of the
152. Song EJ, Yim SH, Kim E, Kim NS, Lee KJ. Human Fas-associated factor 1, interacting with ubiquitinated proteins and valosin-containing protein, is involved in the ubiquitin-proteasome pathway. Mol Cell Biol. 2005;25(6): 2511-2524. (Pubitemid 40354643)
153. Altomare DA, Menges CW, Pei J, et al. Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice. Proc Natl Acad Sci U S A. 2009;106(9): 3420-3425.
154. Borczuk AC, Cappellini GC, Kim HK, Hesdorffer M, Taub RN, Powell CA. Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene. 2007;26(4):610-617. (Pubitemid 46160974)
155. Sun X, Wei L, Liden J, et al. Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling. J Pathol. 2005;207(1):91-101. (Pubitemid 41200718)
156. Sartore-Bianchi A, Gasparri F, Galvani A, et al. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res. 2007;13(19):5942-5951. (Pubitemid 47583922)
157. Sun X, Gulyas M, Hjerpe A, Dobra K. Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer Lett. 2006;232(2):161-169. (Pubitemid 43170965)
158. Yuan BZ, Chapman JA, Reynolds SH. Proteasome inhibitor MG132 induces apoptosis and inhibits invasion of human malignant pleural mesothe-lioma cells. Transl Oncol. 2008;1(3):129-140.
159. Gordon GJ, Mani M, Maulik G, et al. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2008;61(4):549-558.
160. Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus C. Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem. 2008;283(19): 13021-11330.
161. Frizelle SP, Grim J, Zhou J, et al. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene. 1998;16(24):3087-3095. (Pubitemid 28318779)
162. Yang CT, You L, Yeh CC, et al. Adenovirus-mediated p14ARF gene transfer in human mesothelioma cells. J Natl Cancer Inst. 2000;92(8):636-641. (Pubitemid 30321306)
163. Yang CT, You L, Uematsu K, Yeh CC, Mc Cormick F, Jablons DM. p14ARF modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res. 2001;61(16):5959-5963. (Pubitemid 32762521)
164. Kim KW, Mutter RW, Willey CD, et al. Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests. Int J Radiat Oncol Biol Phys. 2007;67(5):1519-1525. (Pubitemid 46467182)
165. Kim JY, Harvard C, You L, et al. Stathmin is overexpressed in malignant mesothelioma. Anticancer Res. 2007;27(1A):39-44. (Pubitemid 46363314)
166. Wu YJ, Parker LM, Binder NE, et al. The mesothelial keratins: a new family of cytoskeletal proteins identified in cultured mesothelial cells and nonkeratinizing epithelia. Cell. 1982;31(3, pt 2):693-703. (Pubitemid 13223952)
167. Vivo C, Lecomte C, Levy F, et al. Cell cycle checkpoint status in human malignant mesothelioma cell lines: response to gamma radiation. Br J Cancer. 2003;88(3):388-395. (Pubitemid 36308149)
168. Bunderson-Schelvan M, Erbe AK, Schwanke C, Pershouse MA. Suppression of the mouse double minute 4 gene causes changes in cell cycle control in a human mesothelial cell line responsive to ultraviolet radiation exposure. Environ Mol Mutagen. 2009;50(9):753-759.
169. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366(9483):397-408. (Pubitemid 41073959)
170. Jin L, Amatya VJ, Takeshima Y, Shrestha L, Kushitani K, Inai K. Evaluation of apoptosis and immunohistochemical expression of the apoptosis-related proteins in mesothelioma. Hiroshima J Med Sci. 2010;59(2):27-33.
171. Lu Q, Harrington EO, Rounds S. Apoptosis and lung injury. Keio J Med. 2005;54(4):184-189. (Pubitemid 43200933)
172. Liu W, Bodle E, Chen JY, Gao M, Rosen GD, Broaddus VC. Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am J Respir Cell Mol Biol. 2001; 25(1):111-118. (Pubitemid 32682713)
173. Rippo MR, Moretti S, Vescovi S, et al. FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene. 2004; 23(47):7753-7760. (Pubitemid 39457025)
174. Tomasetti M, Rippo MR, Alleva R, et al. Alpha-tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells. Br J Cancer. 2004;90(8):1644-1653. (Pubitemid 38648251)
175. Abayasiriwardana KS, Barbone D, Kim KU, et al. Malignant mesotheli-oma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim. Mol Cancer Ther. 2007;6(10):2766-2776. (Pubitemid 350058156)
176. Pespeni MH, Hodnett M, Abayasiriwardana KS, et al. Sensitization of mesothelioma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by heat stress via the inhibition of the 3-phosphoinositide-dependent kinase 1/Akt pathway. Cancer Res. 2007;67(6):2865-2871. (Pubitemid 46548977)
177. Katz SI, Zhou L, Chao G, et al. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol Ther. 2009;8(24):2406-2416.
178. Wilson SM, Barbone D, Yang TM, et al. mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol. 2008;39(5):576-583.
179. Soini Y, Kinnula V, Kaarteenaho-Wiik R, Kurttila E, Linnainmaa K, Paakko P. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin Cancer Res. 1999;5(11):3508-3515.
180. Smythe WR, Mohuiddin I, Ozveran M, Cao XX. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J Thorac Cardiovasc Surg. 2002;123(6):1191-1198.
181. Cao X, Rodarte C, Zhang L, Morgan CD, Littlejohn J, Smythe WR. Bcl2/ bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothe-lioma. Cancer Biol Ther. 2007;6(2):246-252. (Pubitemid 46641630)
182. Littlejohn JE, Cao X, Miller SD, et al. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. Int J Cancer. 2008;123(1):202-208. (Pubitemid 351705210)
183. Varin E, Denoyelle C, Brotin E, et al. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis. 2010;31(6):984-993.
184. O'Kane SL, Pound RJ, Campbell A, Chaudhuri N, Lind MJ, Cawkwell L. Expression of bcl-2 family members in malignant pleural mesothelioma. Acta Oncol. 2006;45(4):449-453. (Pubitemid 43884613)
185. Xia C, Xu Z, Yuan X, et al. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther. 2002;1(9):687-694.
186. Zaffaroni N, Costa A, Pennati M, et al. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol. 2007; 29(6):453-466. (Pubitemid 350136500)
187. Kleinberg L, Lie AK, Florenes VA, Nesland JM, Davidson B. Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. Hum Pathol. 2007;38(7):986-994. (Pubitemid 46899149)
188. Symanowski J, Vogelzang N, Zawel L, Atadja P, Pass H, Sharma S. A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. J Thorac Oncol. 2009;4(2):149-160.
189. Dhaene K, Hübner R, Kumar-Singh S, Weyn B, Van Marck E. Telomerase activity in human pleural mesothelioma. Thorax. 1998;53(11):915-918. (Pubitemid 28494328)
190. Villa R, Daidone MG, Motta R, et al. Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin Cancer Res. 2008;14(13):4134-4140.
191. Catalano A, Romano M, Robuffo I, Strizzi L, Procopio A. Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity. Am J Pathol. 2001;159(2):721-731. (Pubitemid 32751102)
192. Amin W, Parwani AV, Schmandt L, et al. National Mesothelioma Virtual Bank: a standard based biospecimen and clinical data resource to enhance translational research. BMC Cancer. 2008;8:236.